Risk on - This is definitely a risky trade. UBS analysts think that Mounjaro could generate peak annual sales of $25 billion, making it the best-selling . Brian Orelli: Yeah. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Shares of medical technology companyNano-X Imaging (NNOX 68.41%), also known as Nanox, skyrocketed on Monday after the company received clearance from the Food and Drug Administration (FDA) for its flagship medical device. Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Reata expects the drug to be available commercially in the second quarter of 2023. Also benefits from the approval because it's partnered with Biogen on Aduhelm, and other Alzheimer's disease drugs. Orelli: I don't see why not, although I think the difference maybe is that Biogen has this convoluted clinical trial data that also shows that improved cognition in one study. Tesla stock rose above a key level early Tuesday as China sales rebounded in May, easing concerns. Follow Allison Gatlin on Twitter at @IBD_AGatlin. NYSE and AMEX data is at least 20 minutes delayed. That's right -- they think these 10 stocks are even better buys. Therefore, there's financial risk to be aware of as well. Drugmakers can often pick up. In the example illustrated below, Novo Nordisk was given an update by the FDA on 5/3/17 (PD Update) that it could expect a decision on Fiasp on 9/29/17 (forward-looking PD-Expect date). Total revenues, comprising collaboration revenues, were $2.2 million in 2022 compared with $11.5 million in 2021. No cash balance or cash flow is included in the calculation. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. 2000-2023 Investor's Business Daily, LLC. George Budwell has no position in any of the stocks mentioned. Skyclarys, for its part, is expected to rake in approximately $400 million in U.S. sales in 2030. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. This disease, which is usually diagnosed during adolescence, causes progressive loss of coordination, muscle weakness and fatigue, eventually resulting in loss of mobility and finally death. The company's pipeline features several promising programs, as well. Elanco Animal Health Inc. received conditional approval from the Food and Drug Administration on Monday for its drug Varenzin-CA1 to treat anemia in cats with chronic kidney disease. Shares of medical technology company Nano-X Imaging (NASDAQ: NNOX), also known as Nanox, skyrocketed on Monday after the company received clearance from the Food and Drug Administration (FDA). *Real-time prices by Nasdaq Last Sale. In short, this stock's price is prone to strong, emotion-driven moves propelled by both bulls and bears. KemPharm is eligible to receive up to $468 million in milestone payments as well as royalties from sales of the prodrug. The Centers for Disease Control and Prevention estimatesthat8.4% of children and 2.5% of adults in the US have ADHD. It needs to manufacture, find places to install, ship, and deploy its machines. A developer of cellular therapies to treat cancer and diabetes, this is another one of the biotech penny stocks that could make big moves once it has updates from the FDA. Thats on top of the stock almost tripling in the past year. Nanox stock rose by 60% Monday morning, but it's still down 89% from its all-time high. zone: Popup - MM, 89BIO is expected to report its fourth-quarter results next month. PTC Therapeutics expects to report results from the MOVE-FAphase III study on vatiquinone in the second quarter of 2023. ARDS is a life-threatening condition in which the lungs can't provide the body's vital organs with enough oxygen. *Stock Advisor returns as of June 7, 2021. Learn More. Reata has priced Skyclarys at an annual cost of $370,000. The therapy was studied in the GEMINI clinical study, which involved over 1,100 patients, and the drug was found to be statistically superior to a placebo in alleviating depressive symptoms. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Protected by copyright of the United States and international treaties. Reata Pharmaceuticals (RETA Quick QuoteRETA - Free Report) stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an ultra-rare disease called Friedreichs ataxia. Orelli: That trades over-the-counter. This week, Reata Pharmaceuticals' stock bolted higher in response to the FDA approval of its Friedreich's ataxia candidate. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. ados.run = ados.run || []; size: 550x425 - 550 x 425 */ Delayed quotes by FIS. Axsome is focused on developing therapies for central nervous system (CNS) conditions. Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? The FDA actually gave a broad label to Skyclarys. Learn how to trade stocks like a pro with just 3 email lessons! 2023 Money Morning All Rights Reserved. I guess maybe it does seem reasonable that Lilly got bid up on the news, but we have to see what Lilly actually wants to do. Is SoFi Stock a Buy Now? Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Access your favorite topics in a personalized feed while you're on the go. Veru stock collapsed Thursday after the FDA's advisors voted against the company's cancer drug turned Covid treatment. There are no currently approved disease-modifying therapies forFriedreichs ataxia, which means Reata will enjoy the first-mover advantage for some time. A panel of independent experts will decide whether the benefits of Veru's (VERU) drug, dubbed VERU-111, outweigh its risks in some Covid patients. Realtime quote and/or trade prices are not sourced from all markets. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. It is uncertain whether or not it will be marketed as Mounjaro in the weight-loss indication if it's approved. Vowst, formerly called . Why Is SoFi Stock Down After Earnings? The FDA briefing documents come ahead of an advisory committee meeting set for Wednesday. Comment on This Story Click here to cancel reply. In Nanox's annual report, filed Monday, management said it received FDA clearance for its multi-source device on April 28. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. May. Why Reata Pharmaceuticals Stock Skyrocketed This Week (Motley Fool)-6.83%. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Is SoFi Stock a Buy Now? However, the company still has a long road ahead. Moreover, it seemed like the FDA's review process would never end. Then of course Eisai (ESALY -1.03%), is that how you'd say it, Eisai? Save my name, email, and website in this browser for the next time I comment. Sales for cancer drug Verzenio skyrocketed 60% to almost $751 million. Entering text into the input field will update the search result below. RETA - Free Report) stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an ultra-rare. Nano-X Imaging shares jumped more than 45% after the FDA approved Nanox.ARC X-ray system. If approved, commercial sales from Narcan could jump to over $200 million, as projected by Indivior. You can see the complete list of todays Zacks #1 Rank stocks here. We use cookies to understand how you use our site and to improve your experience. That's right -- they think these 10 stocks are even better buys. Shares of biopharmaceutical company Axsome Therapeutics ( AXSM) are up substantially in today's trading session after its depression therapy gained approval from the U.S. Food and Drug Administration (FDA). Your email address will not be published. If you're a patient investor, I think the answer is yes. After eight weeks, the infection rate was 12.8% in the Vowst group compared with 39 . Moreover, in its annual report, Nanox management says, "We expect that we will need to obtain additional financing to implement our business plan." The stock jumped nearly 26% year to date by early March. To make the world smarter, happier, and richer. Cost basis and return based on previous market day close. PTC Therapeutics vatiquinone has been granted Orphan Drug Designation and Fast Track Designation by the FDA. TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions. Privacy Policy | No cost, no obligation to buy anything ever. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Reatas stock jumps 175% in premarket trading after FDA approval (MarketWatch) 07:17AM: Why Reata Pharma Shares Are Skyrocketing Today (Benzinga) 07:14AM: All of that said, Nanox took a massive step forward on Monday, and it's understandable why the market was so fired up about it. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. From there, it intends to make its money on a per-image basis and from its software. The Motley Fool has a disclosure policy. Having investigated AZSTARYS and directly observed its clinical impact on patients, I believe this product will be an important new tool for physicians to use in providing effective care for patients with ADHD.". 89BIOs earnings beat estimates in three of the trailing four quarters, delivering an average earnings surprise of 10.08%. However, the company intends to build its business around its multi-source device, and it didn't have FDA clearance for that one. decreased holdings in the stock by 101,900 shares. Are there any other stocks investors might want to check out as well? The news sent Veru stock close to a record high in August. The average earnings surprise for EFTR is 104.56%. The prodrug was praised by Dr. Ann Childress, President of the Center for Psychiatry and Behavioral Medicine. ET, Nanox stock was up by a whopping 60%. *Average returns of all recommendations since inception. Apr 26, 2023. Gocovri has been approved to treat. Data from the MOXIe Part 2 study showed that treatment with Skyclarys led to statistically significant lower impairment in patients with Friedreichs ataxia compared to placebo at Week 48. Shares of Catalyst Pharmaceuticals, Inc. CPRX increased almost 4% on Feb 13 after the company announced positive results from a recent Type C meeting with the FDA on the resubmission of a new drug application (NDA) for its marketed drug, Firdapse (amifampridine phosphate). Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. They just revealed what they believe are the ten best stocks for investors to buy right now and Eli Lilly and Company wasn't one of them! document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() ); Shares of medical technology company Nano-X Imaging (NASDAQ: NNOX), also known as Nanox, skyrocketed on Monday after the company received clearance from the Food and Drug Administration (FDA) for its flagship medical device. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. KemPharm uses Ligand Activated Therapy (LAT) to discover and develop prodrugs which are used to improve a drug's bioavailability, extend its duration of action, reduce its susceptibility to abuse, and/or increase safety. ados_load(); In the case of. ALLISON GATLIN. Loss estimates for 89BIO for 2023 have narrowed from $2.67 per share to $2.59 per share in the past 60 days. Under the License Agreement, KemPharm will be eligible for up to $468 million in regulatory and sales milestone payments, as well as significant tiered royalty payments. The Motley Fool has a disclosure policy. .setZone(136136); Speights: Brian, do you think the fact that the FDA has granted accelerated approval for Aduhelm. See our report's 7 new picks today, absolutely FREE. No representations and warranties are made as to the reasonableness of the assumptions. Under the Inflation Reduction Act, the Centers for Medicare and Medicaid Services will begin negotiating the prices of the most expensive medicines the agency buys. The analyst expects Fotivda to rule the roost, at least until generics enter in . If you would like to customise your choices, click 'Manage privacy settings'. That's a big opportunity for a company with a market cap of $3.1 billion at the time of this writing. 5 Ways to Beat the Fed (and Crush Inflation), Norwegian Cruise Line (NCLH) Q1 2023 Earnings Call Transcript, The Next $1.8 Trillion Tech Bull Run Is Starting Now - Here's What to Do, Do Not Sell or Share My Personal Information. Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. Brian Orelli, PhD has no position in any of the stocks mentioned. As of 10:30 a.m. FDA clearance is a big deal for Nanox. The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Markets Close Flat After Eventful Day; MGM, NXPI, CHGG Beat in Q1, Buy the Opportunity in These Stocks After Earnings, Top Stock Reports for AMD, Cigna & Moderna, Market Leader NVIDIA Breaking Out on Volume. The monthly returns are then compounded to arrive at the annual return. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Please disable your ad-blocker and refresh. However, hedge funds are yet to catch the Axsome train and havedecreased holdings in the stock by 101,900 sharesin the last quarter. Click here to jump to comments. Biogen (BIIB 2.26%) stock skyrocketed after its Alzheimer's disease drug Aduhelm won U.S. Food and Drug Administration (FDA) approval. Wall Street, though, is more optimistic, with a Moderate Buy consensus rating and anaverage AXSM price target of $69.11, which implies 21.8% upside potential. Friedreichs ataxia is an ultra-rare genetic, progressive, neurodegenerative movement disorder that affects approximately 5,000 diagnosed patients in the United States. Viking Therapeutics Inc. ( VKTX . In Nanox's annual report, filed Monday, management said it received FDA clearance for its multi-source device on April 28. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. As of 10:30 a.m. The recommended dosage of Skyclarys is 150 mg taken orally once daily. Today, you can download 7 Best Stocks for the Next 30 Days. Nanox.ARC is a "multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X-ray tubes." Actual performance may differ significantly from backtested performance. Join the conversation. Although prodrugs aren't well known, an estimated 10% of drugs worldwide are considered to be prodrugs. The TipRanks Smart Score performance is based on backtested results. The . Nanox.ARC is a "multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X . Moreover, in its annual report, Nanox management says, "We expect that we will need to obtain additional financing to implement our business plan." The FDA based its approval on Phase 3 results showing Vowst reduced the rate of recurrence of C. diff infection. "Today's approval highlights both the value potential of SDX, our prodrug of d-MPH, and the ability of our LAT platform technology to develop new prodrugs of approved medications that improve one or more of the attributes of the parent drug," the CEO added. Learn More. Shares of KemPharm skyrocketed as much as 90% on Wednesday after the FDA approved the company's once-daily treatment for ADHD called Azstarys. Get market updates, educational videos, webinars, and stock analysis. Sign up for our newsletter to get the inside scoop on what traders are talking about delivered daily to your inbox. Nanox stock rose by 60% Monday morning, but it's still down 89% from its all-time high. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Biogen 's ( BIIB 1.28%) Alzheimer's disease drug Aduhelm (aducanumab) on Monday. Now what Nanox stock rose by 60% Monday morning, but it's still down 89% from its all-time high. Still, Veru stock surged to a two-month high Monday. PTC Therapeutics, Inc. (PTCT) - free report >>, Reata Pharmaceuticals, Inc. (RETA) - free report >>, eFFECTOR Therapeutics, Inc. (EFTR) - free report >>. Is Reata's stock a buy on this news? Seres Therapeutics Inc. shares were down 13%, to $5.61, after the company said the U.S. Food and Drug Administration approved Vowst and has entered into a new debt facility. We, Yahoo, are part of the Yahoo family of brands. Can Earnings Recharge Electric Vehicle Stocks? Real time prices by BATS. In my research and practice, three properties are repeatedly cited by patients and their caregivers as being underserved by current ADHD medications: onset of action, duration of effect and consistency of therapy. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. Do you think Lilly might be a winner in Alzheimer's disease drug market over the long run? Dan V. Iosifescu, MD, Professor of Psychiatry at the New York University School of Medicine and Director of Clinical Research Division at the Nathan Kline Institute for Psychiatric Research, commented, In clinical trials, Auvelity has demonstrated rapid and statistically significant improvement in depressive symptoms as early as Week 1, and increased rates of remission at Week 2 compared to Placebo.. }); Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience for free. By Mary de Wet. Veru stock skyrocketed Monday after the Food and Drug Administration posted a mixed review of its repurposed cancer drug for Covid treatment. The clearance applies to both Nanox's medical device and the accompanying software known as the Nanox.CLOUD. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. R&D expenses were $169.8 million in 2022, up almost 9% year over year. In short, this stock's price is prone to strong, emotion-driven moves propelled by both bulls and bears. Reata expects patients to gain access through insurance and a patient-assistance program. Want to learn more about investing? Get access to free IBD eventsonline & in-person! Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content. Morgan Stanleys (MS)Vikram Purohitrecently reiterated a Hold rating on the stock alongside a price target of $55. Veru stock skyrocketed Monday after the Food and Drug Administration posted a mixed review of its repurposed cancer drug for Covid treatment. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli. Shares of 89BIO have increased 249.1% in the past year. ados.run.push(function() { Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. The FDA granted Breakthrough Therapy designation to teplizumab and priority review designation for the marketing application. Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information. Here's what lit a fire beneath these three biotech stocks and . Required fields are marked *, Sign me up for the Money Morning newsletter. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Make more money in stocks with 2 months of access to IBD Digital for only $20! Loss estimates for eFFECTOR Therapeutics for 2023have narrowed from 96 cents to 88 cents in the past 60 days. Why Is SoFi Stock Down After Earnings? Your email address will not be published. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Veru had enrolled an additional 54 patients at that point. Friedreich's. If you do not, click Cancel. 04:03 PM ET 04/25/2023. . In addition to the approval, the FDA also granted Reata a rare pediatric disease priority review voucher. /* load placement for account: Money Map Press, Skyclarys is the first drug to be approved specifically for the treatment of Friedreichs ataxia and is also Reatas first commercial product. Visit Performance Disclosure for information about the performance numbers displayed above. This information is provided for illustrative purposes only. This means Veru stock ranks in the leading 6% of all stocks in terms of 12-month performance, according to IBD Digital. Some better-ranked stocks in the biotech sector include eFFECTOR Therapeutics (EFTR Quick QuoteEFTR - Free Report) and 89BIO (ETNB Quick QuoteETNB - Free Report) . Ann Childress, M.D. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss two stocks that could also be winners along with Biogen. That's not a bad start for a newly approved rare disease medicine, but it is also far from the upper end of the drug's long-term commercial opportunity. Cost basis and return based on previous market day close. Because it didn't seem like it was working and then they passed the data and looked at only the patients who got a high level of the drug, and they showed that it works. Childress said: "The ADHD industry, and specifically the MPH space, has seen little innovation in recent years, leaving prescribers and patients desiring new treatment options. Still, the FDA said Veru would need at least 300 patients to show a statistically significant result. Several analysts hiked their price targets on the stock after the FDAs approval for Skyclarys. Invest better with The Motley Fool. That makes the FDA's approval of Nanox.CLOUD just as important as its approval of the device itself. The company still has to execute on the rest of its plan, and management expects that it will need to raise more money to do that. Recent stocks from this report have soared up to +178.7% in 3 months - this month's picks could be even better. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Avadel Pharmaceuticals plc's (NASDAQ:AVDL) shares are up Monday after the FDA granted final approval to Lumryz, an extended-release formulation of sodium oxybate indicated . If it surprisingly goes in the opposite direction, the stock could have an exaggerated move. 1, 2023, 02:34 PM. But it's necessary for investors to be aware of how much more work the company has to do. For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate., Invest Like a Pro with Unique Data & Simplifed Tools, Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting, Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference, Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8. An example of the value driving power of a good late-stage clinical readout is Sage Therapeutics (NASDAQ: SAGE) shares skyrocketed as much as 85 percent to hit a record high after announcing. Eli Lilly (LLY) Q1 2023 Earnings Call Transcript. Zacks Ranks stocks can, and often do, change throughout the month. Opiant plans to file for clearance of Narcan with the U.S. Food and Drug Administration (FDA) by the end of 2022. I think it's more of a guess at this point on whether Lilly is actually more valuable based on this FDA news. From there, it intends to make its money on a per-image basis and from its software. The Food and Drug Administration granted Biogen ( BIIB) an accelerated approval Tuesday for a drug that treats a muscle-wasting disease known as ALS. But the study was small, involving just 150 patients. Sign up for free today. Shares of the rare disease specialist Reata Pharmaceuticals (RETA 0.94%) jumped by 94.1% over the first three and a half days of trading this week, according to data provided byS&P Global Market Intelligence. Wall Street is eyeing more gains from the stock. Why I Refuse to Chase the Maximum Social Security Benefit, U.S. Money Supply Is Doing Something It Hasn't Done in 90 Years, and It May Signal a Big Move for Stocks. The company hit highs of $18.72 per share on December 18 of last year and has seen its stock fall since, but the recent FDA approval was a game-changer for the biotech firm, accord to the company's CEO. The companys net loss was $311.9 million in 2023, wider than $297.4 million in 2021. And each of these steps comes with execution risks. Making the world smarter, happier, and richer. ET, Nanox stock was up by a whopping 60%. Shares of KemPharm skyrocketed as much as 90% on Wednesday after the FDA approved the company's once-daily treatment for ADHD called Azstarys. By clicking Sign up, you agree to receive marketing emails from Insider But it also believes the same drug could help hospitalized patients with moderate to severe Covid who are also at heightened risk of acute respiratory distress syndrome, or ARDS. They just revealed what they believe are the ten best stocks for investors to buy right now and Nano-X Imaging wasn't one of them! You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. See. Reata Pharmaceuticals RETA stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an. and President of the Center for Psychiatry and Behavioral Medicine, noted the positive results of the Azstarys clinical trial in a statement. The Food and Drug Administration pushed its review date for Amylyx Pharmaceuticals ' ( AMLX) controversial ALS treatment on Friday, and the biotech stock skyrocketed. Cost basis and return based on previous market day close. But both camps should strive to keep emotions in check. More than 20 million adults in the U.S. suffered from major depressive disorder (MDD) annually before the COVID-19 pandemic, and the number increased to over 80 million adults during the pandemic. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. 3 Stocks That Already Doubled in 2023 and Could Keep Climbing, 3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing, The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February, Why Reata Pharmaceuticals Stock Is Soaring Today, Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday, Why I Refuse to Chase the Maximum Social Security Benefit, U.S. Money Supply Is Doing Something It Hasn't Done in 90 Years, and It May Signal a Big Move for Stocks.
Listen To Mojo In The Morning Live,
Normandy Barracks Sennelager,
Articles S